

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Check this box to indicate that a
transaction was made pursuant to a
contract, instruction or written plan for
the purchase or sale of equity
securities of the issuer that is intended
to satisfy the affirmative defense
conditions of Rule 10b5-1(c). See
Instruction 10.

1. Name and Address of Reporting Person* <u>Kelsey Stephen Michael</u> (Last) (First) (Middle) <u>REVOLUTION MEDICINES, INC.</u> <u>700 SAGINAW DRIVE</u> (Street) <u>REDWOOD</u> <u>CA</u> <u>94063</u> <u>CITY</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Revolution Medicines, Inc. [RVMD]</u> Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) <u>09/11/2026</u> 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner ☒ Officer (give title below) Other (specify below) <u>See Remarks</u> 6. Individual or Joint/Group Filing (Check Applicable Line) ☒ Form filed by One Reporting Person Form filed by More than One Reporting Person
---	--	---

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	09/11/2026		M ⁽¹⁾		52,500	A	\$42.45	344,376	D	
Common Stock	09/11/2026		M ⁽¹⁾		40,031	A	\$40.74	384,407	D	
Common Stock	09/11/2026		S ⁽¹⁾		800	D	\$198.5502 ⁽²⁾	383,607	D	
Common Stock	09/11/2026		S ⁽¹⁾		11,833	D	\$200.1145 ⁽³⁾	371,774	D	
Common Stock	09/11/2026		S ⁽¹⁾		13,368	D	\$200.7769 ⁽⁴⁾	358,406	D	
Common Stock	09/11/2026		S ⁽¹⁾		21,447	D	\$201.7507 ⁽⁵⁾	336,959	D	
Common Stock	09/11/2026		S ⁽¹⁾		18,869	D	\$203.0606 ⁽⁶⁾	318,090	D	
Common Stock	09/11/2026		S ⁽¹⁾		17,949	D	\$203.8726 ⁽⁷⁾	300,141	D	
Common Stock	09/11/2026		S ⁽¹⁾		4,995	D	\$204.8427 ⁽⁸⁾	295,146	D	
Common Stock	09/11/2026		S ⁽¹⁾		3,270	D	\$205.8075 ⁽⁹⁾	291,876 ⁽¹⁰⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$42.45	09/11/2026		M ⁽¹⁾		52,500	(11)	03/04/2031	Common Stock	52,500	\$42.45	0	D	
Stock Option (Right to Buy)	\$40.74	09/11/2026		M ⁽¹⁾		40,031	(12)	03/01/2035	Common Stock	128,100	\$40.74	88,069	D	

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026.

2. The transaction was executed in multiple trades at prices ranging from \$198.35 to \$198.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. The transaction was executed in multiple trades at prices ranging from \$199.36 to \$200.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

4. The transaction was executed in multiple trades at prices ranging from \$200.36 to \$201.33, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

5. The transaction was executed in multiple trades at prices ranging from \$201.39 to \$202.37, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective

12. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Senior Advisor to the Chief Executive Officer

/s/ Jack Anders, as Attorney-in-
fact for Stephen Michael 09/15/2026
Kelsey

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.